Cytek Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Cytek Biosciences

09/11/2022 22:47

* Cytek Biosciences Inc  CTKB.OQ  reported quarterly
adjusted
earnings of 4 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for earnings of 2 cents per share.
    * Revenue fell 36.6% to $40.48 million from a year ago;
analysts
expected $43.29 million. 
    * Cytek Biosciences Inc's reported EPS for the quarter was 1
cent​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cytek Biosciences Inc shares had fallen by 1.4% this
quarter and
lost 11.0% so far this year.
    * The company reported quarterly net income of $1.63
million.
    * Wall Street's median 12-month price target for Cytek
Biosciences
Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 10:47 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      0.02           0.04           Beat
 Jun. 30 2022      0.02           0.03           Beat
 Mar. 31 2022      0.00           0.01           Beat
 Dec. 31 2021      0.03           0.03           Met